Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Intravenous Transplantation of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells and a Change in Chronic Pain.

Mabuchi K., Takahashi Y., Iketani M., Okinaka Y., Satani S., Takesaka T.

Randomized Controlled Trial with a reported sample of 28 on Chronic Inflammation, published in Stem Cells Dev (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Stem Cells Dev (2025)
Country
United States
Reported sample size
28
Source database
PubMed
PMID
40586481
DOI
10.1089/scd.2025.0065

Abstract (original English)

Globally, more than 300 million individuals experience chronic pain. Chronic inflammation with increased infiltration of activated inflammatory cells is a major cause of chronic pain. Mesenchymal stem cells (MSCs) are known to suppress excessive inflammation, and their mechanism of action has been shown to be a gap junction-mediated interaction with the endothelium and circulating white blood cells. In vitro-expanded autologous adipose tissue-derived MSC were transplanted intravenously into patients with chronic pain. The degree of pain was evaluated before and after treatment using the Faces Pain Scale and Pain Disability Assessment Scale. This study included 28 patients. The potential of MSCs for gap junction-mediated transfer of small water-soluble molecules was evaluated in vitro. Autologous adipose tissue-derived MSC significantly attenuated chronic pain compared with pain before cell transplantation. In vitro analysis confirmed that about 80% of transplanted MSC could transfer small molecules via gap junctions. Our results indicate that transplantation of in vitro-expanded adipose tissue-derived MSC, which can transfer small molecules via gap junctions, is safe and may suppress chronic pain. Further double-blinded clinical studies are required to confirm the effect.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansChronic PainMesenchymal Stem Cell TransplantationAdipose TissueMesenchymal Stem CellsMaleTransplantation, AutologousMiddle AgedFemaleAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research